Genomics

Dataset Information

22

Homo sapiens


ABSTRACT: NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules

ORGANISM(S): Homo sapiens  

PROVIDER: PRJNA278663 | ENA |

REPOSITORIES: ENA

altmetric image

Publications

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Trudeau Maureen Elizabeth ME   Chapman Judith-Anne W JA   Guo Baoqing B   Clemons Mark J MJ   Dent Rebecca A RA   Jong Roberta A RA   Kahn Harriette J HJ   Pritchard Kathleen I KI   Han Lei L   O'Brien Patti P   Shepherd Lois E LE   Parissenti Amadeo M AM  

SpringerPlus 20151021


This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally-tolerated doses (MTD), dose-limiting toxicities, response-to-therapy, and explored the role of novel response biomarkers. MA.22 accrued T3N0, any N2 or N3, and T4 breast cancer patients. Treatment was 6 cycles of 3-weekly (Schedule A; N = 47) or 8 cycles of 2-weekly (Schedule B; N = 46) epirubicin/docetaxel chemotherapy in sequential phase I/II studies, with growth factor support. In phase I of eac  ...[more]

Similar Datasets

2015-11-11 | E-GEOD-66999 | ArrayExpress
2011-02-07 | E-GEOD-23988 | ArrayExpress
2011-02-07 | GSE23988 | GEO
| GSE87455 | GEO
2008-06-15 | E-GEOD-6861 | ArrayExpress
2017-03-30 | E-MTAB-5198 | ArrayExpress
2008-12-19 | E-GEOD-4779 | ArrayExpress
2016-10-25 | E-MTAB-4854 | ArrayExpress
| GSE48667 | GEO
| GSE58837 | GEO